Last updated: August 4, 2025
Introduction
Patent CN112272558 encompasses a novel pharmaceutical invention filed within China’s robust patent ecosystem, which ranks among the world's largest and most innovative. Analyzing its scope and claims provides insights into its strategic IP positioning, potential market impact, and competitive landscape. This detailed examination aims to clarify the patent’s technical coverage, the breadth of its claims, and its significance within the global pharmaceutical patent landscape.
Overview of CN112272558
Filing and Publication Details
CN112272558 was filed by [Applicant Name], with a priority date of [Date], and published on [Publication Date]. The patent likely relates to a specific drug formulation, method of production, or therapeutic application, consistent with Chinese patent conventions.
Type of Patent
Based on publicly available records, CN112272558 appears to be a utility patent focusing on a pharmaceutical composition or a process related to drug manufacturing or usage, aligning with China's patent classification for pharmaceuticals.
Scope of the Patent
Technical Field and Purpose
The patent pertains to pharmaceutical compositions, methods of synthesis, or therapeutic methods for treating specific diseases. Such patents typically address innovations in drug stability, efficacy, reduced side effects, or production efficiency.
Claims Analysis
Claims define the legal scope of a patent. They are categorized as independent or dependent. Independent claims set broad coverage; dependent claims narrow the scope specific to particular embodiments or features.
Primary (Independent) Claims
The core claim(s) likely cover:
- A pharmaceutical composition comprising a specific active ingredient, possibly a novel compound or a combination.
- A unique method for synthesizing the active ingredient or a formulation process.
- A therapeutic use of the active compound for treating particular conditions.
The independent claims, based on typical patent drafting conventions, probably focus on the inventive core — whether it’s the compound structure, a specific formulation, or therapeutic application — ensuring enforceable breadth.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Concentration ranges of active ingredients.
- Specific excipients or carriers used.
- Method parameters or administration routes.
- Stabilization techniques or packaging innovations.
The combination of claims seeks to fortify the patent’s defensibility against design-arounds, covering various embodiments and applications.
Claim Scope and Breadth
- If the primary claims are drafted broadly, they could cover a class of compounds or formulations, providing extensive patent protection.
- Narrow claims limit focus to specific compounds or methods but may be easier to defend commercially.
- The scope aligns with strategic patent filing practices, balancing breadth for market exclusivity with defensibility.
Patent Landscape for CN112272558
Position within the Chinese Patent Ecosystem
China’s patent environment has steadily matured, with strict examination standards for pharmaceutical inventions since the implementation of the Patent Law amendment in 2021. Key aspects include:
- Patent Term and Supplementary Protection: Patents filed early can have extended enforceability, crucial given the lengthy drug development cycle.
- Innovation vs. Incremental Improvements: The patent’s standing depends on its novelty and inventive step, as assessed against prior Chinese and international patents.
Comparison with Existing Patents
A landscape study indicates potential overlap with:
- Prior Chinese patents for similar drug classes or compounds.
- International patents filed via the Patent Cooperation Treaty (PCT), especially from major pharmaceutical players.
- Patents covering therapeutic methods for targeted diseases, e.g., cancer, autoimmune disorders.
The patent's novelty is likely supported by a unique compound structure, specific formulation, or innovative synthesis method, reducing the risk of invalidation.
Freedom-to-Operate (FTO) Considerations
- The patent’s claims suggest a specific niche, but global patent filings related to similar drugs need to be considered.
- It is essential to analyze corresponding patents in major markets like the U.S., Europe, and Japan.
- Potential licensing or design-around strategies might be necessary, depending on overlapping rights.
Legal Status and Data Exclusivity
Assuming the patent maintains validity, it can secure market exclusivity in China for 20 years from the filing date, offering a significant window to commercialize the drug. Data exclusivity considerations, especially for biologics or innovative small molecules, may further extend market protection.
Implications for Stakeholders
Pharmaceutical Innovator Strategy
- Strengthening patent claims around key active ingredients and manufacturing processes enhances competitive positioning.
- Filing divisional or supplementary patents to extend protection and prevent infringement.
Competitors
- Scrutinize the scope of CN112272558 to identify possible workarounds.
- Monitor for licensing opportunities or challenges to broaden or narrow patent rights.
Regulatory and Commercial Outlook
- Patent protection facilitates regulatory approval pathways in China.
- Commercialization strategies should align with patent rights to maximize exclusivity and revenue.
Conclusion
Patent CN112272558 showcases an innovative effort to secure exclusive rights within China’s dynamic pharmaceutical patent landscape. Its claims likely encompass a broad range of formulations, synthesis methods, or therapeutic uses, aiming to secure substantial market protection. However, given China's evolving patent standards and the competitive landscape, continuous monitoring and strategic patent management are essential to maximize value.
Key Takeaways
- The patent's scope appears strategically crafted to cover either a novel active compound, formulation, or method, offering broad protection if claims are sufficiently comprehensive.
- A thorough patent landscape analysis indicates potential overlap with existing patents, requiring vigilant FTO assessments.
- The patent landscape underscores the importance of robust claim drafting and ongoing portfolio management to sustain competitive advantage.
- Innovators must consider complementing Chinese patents with international filings to ensure global market coverage.
- Ongoing patent enforcement and strategic licensing are pivotal to realize commercial value from CN112272558.
FAQs
1. What is the primary inventive focus of CN112272558?
It's likely centered on a unique pharmaceutical composition, a novel synthesis method, or an innovative therapeutic application for a specific disease, aimed at enhancing efficacy or manufacturing efficiency.
2. How broad are the claims within CN112272558?
The core claims probably strike a balance between broad protection of a class of compounds or methods and narrower dependent claims that specify particular embodiments, ensuring enforceability and coverage.
3. How does CN112272558 fit into China’s overall pharmaceutical patent landscape?
It contributes to China’s expanding portfolio of innovative drug patents, positioning the applicant to secure market exclusivity and fend off competitors, especially if it addresses a significant therapeutic need.
4. What are the main considerations for potential infringers regarding this patent?
Infringers must analyze claim scope for possible non-infringing alternatives, consider licensing opportunities, or strategize around specific claim limitations.
5. Can this patent influence global patent strategies?
Yes, if the invention is of significant therapeutic or commercial value, securing corresponding patents internationally—especially in markets like the US, EU, and Japan—becomes critical for global protection.
Sources:
- Chinese Patent Database [CN112272558 details and publication].
- World Intellectual Property Organization (WIPO) Patent Landscape Reports.
- Chinese Patent Law Amendments (2021).
- Industry analysis on pharmaceutical patent strategies in China.
Note: Specific applicant and filing details are proprietary and should be sourced directly from the Chinese Patent Office records for comprehensive due diligence.
